Navigation Links
CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
Date:1/4/2008

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today the publication of a European study of atrial fibrillation patients treated with CryoCor's Cardiac Cryoablation System. The purpose of the study was to evaluate the role of atrial flutter in the recurrence of atrial fibrillation and the effectiveness of an ablation strategy focused on isolating the pulmonary veins to treat the atrial fibrillation. The study was published in the December 11, 2007 issue of Circulation.

The 98-patient study was conducted by Dr. Wendel Moreira, Dr. Luz-Maria Rodriguez, Dr. Carl Timmermans and others in Academic Hospital Maastricht using CryoCor's Cardiac Cryoablation System. The study prospectively evaluated the best catheter ablation strategy in patients with paroxysmal atrial fibrillation with and without concomitant right atrial flutter. During follow-up averaging 26 months, the authors found that electrical isolation of the pulmonary veins by catheter ablation was successful in patients without concomitant atrial flutter at an 82% success rate. In patients with concomitant atrial flutter, the combination of ablation for atrial flutter and pulmonary vein isolation alone to treat atrial fibrillation was frequently insufficient in preventing recurrences of atrial fibrillation (recurrence rate of 67%). The authors concluded that those patients with atrial flutter and atrial fibrillation may require additional sites of ablation to effectively treat their atrial fibrillation.

Dr. Rodriguez, senior author of the study, stated, "This is the first time that an ablation strategy for paroxysmal atrial filbrillation and atrial flutter has been systematically studied. This has implications for the tools that a clinician may use to treat these atrial arrhythmias. Based on this study, we do not believe that it will be sufficient to simply isolate the pulmonary veins in a significant proportion of patients."

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the study's results and conclusions drawn from the study's results, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology and the diagnosis and treatment of atrial arrhythmias; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.

Contact:

CryoCor, Inc.

Gregory J. Tibbitts

Chief Financial Officer

(858) 909-2200

gtibbitts@cryocor.com

The Ruth Group

Nick Laudico / Zack Kubow (investors)

(646) 536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCor Files Response to Patent Infringement Lawsuit
2. CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results
3. CryoCor Appoints New Vice President of Sales and Marketing
4. CryoCor to Present at Maxim Group First Annual Growth Conference in New York
5. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
6. FDA Reports New Risks Posed by Anemia Drugs
7. Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement
8. UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007
9. The Ensign Group, Inc. Reports Third Quarter 2007 Earnings
10. HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million
11. Par Pharmaceutical Reports Third-Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year ... be $394.9 billion. The consequences of rapid innovation and growth are often neglected ... technology, it is every business and individual’s job to give something back to the ...
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com released ... save an average of 70% when buying medication online from Canadian pharmacies verified ... when purchasing from other countries. The report (chart below) compares U.S. and foreign ...
(Date:4/22/2017)... Juan Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan Capistrano ... recently released a parenting report outlining the need for summer camps to provide physical activities ... The Importance of Physical Activity In Summer Camps , With an increase in specialty camps ...
(Date:4/21/2017)... ... 2017 , ... Providing broad access to life-saving drugs and rewarding the innovators ... way to address this problem. , That was the message from Dana Goldman, PhD, ... the University of Southern California, who served as the keynote speaker for Western University ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary ... that youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright ... people involved in violence in the United States. The study, Trends in ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology: